Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Dare Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene(R) Licensing Agreement and General Corporate Update

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020,...

DARE : 1.38 (-18.82%)
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022

Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity....

CNSP : 4.43 (+0.91%)
ADAP : 4.03 (+0.75%)
DARE : 1.38 (-18.82%)
VRNA : 5.97 (-7.44%)
PFE : 40.67 (+1.19%)
AXSM : 88.45 (+1.07%)
Bayer and Dare Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene (R), an Investigational Hormone-Free, Monthly Contraceptive

Bayer, a leader in women's health, and Dare Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health, announced...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will give one of the feature presentations at the 15 US-Japan Symposium on Drug Delivery Systems taking...

DARE : 1.38 (-18.82%)
Dare Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc. As...

DARE : 1.38 (-18.82%)
ANIK : 45.88 (+0.37%)
STIM : 4.25 (-0.93%)
Dare Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update.

DARE : 1.38 (-18.82%)
Dare Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene(R) Hormone-Free Contraceptive Candidate

-- Currently marketed contraceptives with similar results in their PCT clinical studies subsequently demonstrated 6-month "typical use" effectiveness of 86-91% in their pivotal clinical trials, in the...

DARE : 1.38 (-18.82%)
Dare Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc. Dare entered into the agreement...

DARE : 1.38 (-18.82%)
Dare Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2019,...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical...

DARE : 1.38 (-18.82%)
Dare Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a...

DARE : 1.38 (-18.82%)
Dare Bioscience to Participate in Two Upcoming Investor Conferences

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo,...

DARE : 1.38 (-18.82%)
Dare Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th annual Partnership Opportunities...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the article entitled "Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local...

DARE : 1.38 (-18.82%)
Dare Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the...

DARE : 1.38 (-18.82%)
Dare Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the H.C. Wainwright 21...

DARE : 1.38 (-18.82%)
Dare Bioscience Reports Second Quarter 2019 Financial Results and Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the second quarter ended June 30, 2019 and provided a Company update.

DARE : 1.38 (-18.82%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +2.92 , SEDG +0.64 , THC +0.22 , TER +2.85 , LITE +0.27
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar